Lazard Asset Management
HARP

Lazard Asset Management’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Lazard Asset Management’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-344
Closed -$57K – 2077
2020
Q4 		$57K Hold
344
– – ﹤0.01% 1346
2020
Q3 		$58K Buy
+344
New +$49.6K ﹤0.01% 1141

Other funds holding HARP

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Lazard Asset Management's HARP Position: Q1 2021 in Review

Lazard Asset Management sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q1 2021, closing a stake of 344 shares — an estimated $57K sold.

Lazard Asset Management first reported a position in HARP in Q3 2020 and held it in 2 quarters. The position peaked at $58K in Q3 2020. 88 funds tracked by Wall St. Rank hold HARP as of Q1 2021.

  • Lazard Asset Management reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Lazard Asset Management sold 344 Harpoon Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $57K.
  • Lazard Asset Management first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q3 2020 and held it in 2 quarters.
  • Lazard Asset Management's Harpoon Therapeutics, Inc. Common Stock position peaked at $58K in Q3 2020.
  • 88 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Lazard Asset Management's 13F filing for Q1 2021, filed 14 May 2021.